Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Show moreShow less
The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Quality Score breakdown
Overall quality43/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability3
How much profit the company makes from its sales and capital
Quality Growth30
Are margins and returns getting better?
Cashflow4
Do the profits arrive as real cash?
Financial strength92
Debt, balance sheet and risk of trouble
Investment85
Does it invest with discipline instead of growing at any price?
Low Volatility24
How calm the share price moves, does not count
Price momentum100
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 5 officers or directors sold shares worth $72.1M and none bought.
SaleStephen HogePresident6× since Feb 23, 2026: 478,961 shares, avg. $94.89$45.4MOct 15, 202610b5-1 plan
SaleJames M MockChief Financial Officer34,836 shares at $134.49$4.7MSep 10, 202610b5-1 plan
SaleShannon Thyme KlingerChief Legal Officer3× since Mar 2, 2026: 20,827 shares, avg. $66.52$1.4MSep 1, 202610b5-1 plan
SaleStephane BancelChief Executive Officer, Director499,246 shares at $57.52$28.7MAug 5, 202610b5-1 plan
SaleNoubar AfeyanDirector2× since Dec 11, 2025: 33,116 shares, avg. $34.34$1.1MMay 21, 2026
SaleAbbas HussainDirector2× since Dec 9, 2025: 6,186 shares, avg. $45.08$278,862May 1, 202610b5-1 plan
Plus 26 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−39.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−53.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.9%
Start year 2020 (pandemic)
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+112.0%
’14
’16
’17
’18
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−278.0% (2020) → −158.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks
Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score43 · Below median
Profitability
Return on assets−22.9% · Below median
Net margin (12 months)−141.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)2.1% · Above median
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
Moderna Inc has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Moderna Inc (MRNA)?
Moderna Inc reported trailing-twelve-month revenue of about $2.2B (latest available figure, as of Nov 7, 2026).
How solid is the balance sheet of Moderna Inc (MRNA)?
Balance-sheet figures for Moderna Inc (as of Nov 7, 2026): return on equity −39.0%, debt of 0.07 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
Which stocks are comparable to Moderna Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Moderna Inc (MRNA)?
The closing price on Nov 6, 2026 was $254.19. We carry closing prices from our data provider, not a live tick.
Key figures of Moderna Inc
How large is the market capitalisation of Moderna Inc (MRNA)?
The market capitalisation of Moderna Inc is $101B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Moderna Inc (MRNA)?
The price-to-sales ratio of Moderna Inc is 45.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Moderna Inc (MRNA)?
Earnings per share at Moderna Inc are $−7.98. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Moderna Inc (MRNA)?
The net margin of Moderna Inc is −141% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Moderna Inc (MRNA)?
The return on equity (ROE) of Moderna Inc is −39.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Moderna Inc (MRNA)?
On an EBIT basis the return on assets of Moderna Inc is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Moderna Inc (MRNA)?
The operating margin of Moderna Inc is −558% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Moderna Inc (MRNA)?
Revenue at Moderna Inc is growing +2.1% versus a year earlier (3y avg −53.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Moderna Inc (MRNA)?
Earnings per share at Moderna Inc are growing −85.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Moderna Inc (MRNA) generate?
The free cash flow of Moderna Inc is −$2.1B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Moderna Inc (MRNA) hold?
Moderna Inc holds more cash than debt, $679M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Moderna Inc in the live analysis
One click puts Moderna Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026